aprogenex
said
tuesday
opinion
arthur
andersen
llp
independent
public
accountants
company
operation
going
concern
dependent
ability
obtain
additional
working
capital
complete
research
development
activities
attain
successful
future
operations.aprogenex
said
currently
cash
resources
fund
operations
june
says
believes
allow
sufficient
time
meet
funding
requirements
company
announced
finalizing
strategy
meet
financial
requirements
focus
1996
application
dna
probe
technology
hiv
testing
securing
partners
develop
prenatal
genetic
probe
products
said
president
chief
executive
david
m
leech
collaborative
agreement
signed
month
centocor
enhance
development
efforts
hiv
area
amcell
corp
bioseparations
agreements
align
companies
focused
cell
separation
genetic
applications
focus
1997
expansion
technology
diagnostics
acquisition
licensing
medical
therapeutics
aprogenex
reported
loss
fourth
quarter
1996
612,212
0.12
share
versus
loss
1,163,668
0.22
share
fourth
quarter
1995
cash
short
term
investments
december
31
1996
totaled
327,400.aprogenex
develops
generation
diagnostic
tests
based
proprietary
dna
probe
technology
